扶正抗癌方治疗晚期非小细胞肺癌疗效的Meta分析  

A Meta-analysis of Efficacy of Fuzheng Kang'ai Formula for Advanced Non-small Cell Lung Cancer

作　　者：高广毅[1] 

机构地区：[1]江苏省淮安市第二人民医院,223000

出　　处：《实用癌症杂志》2017年第5期789-792,共4页The Practical Journal of Cancer

摘　　要：目的探讨扶正抗癌方联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法在中国生物医学文献数据库、Pub Med等数据库检索扶正抗癌方联合化疗治疗晚期NSCLC的随机对照试验(RCT),采用Meta分析专用软件Rev Man 5.2进行系统评价。结果共纳入6个RCT,均为B级文献,共有467例NSCLC患者。Meta分析显示,扶正抗癌方联合化疗治疗晚期NSCLC的有效率优于单纯化疗组,差异有统计学意义[RR=1.87,95%CI(1.28~2.72)];扶正抗癌方联合化疗组的不良反应发生率低于单纯化疗组,差异有统计学意义[RR=0.29,95%CI(0.16~0.54)]。研究无明显发表偏倚。结论现有研究表明,扶正抗癌方联合化疗治疗晚期NSCLC的有效率优于单纯化疗组,且安全性更佳。Objective To study the efficacy and safety of Fuzheng Kang＇ ai formula combined with chemotherapy in treating advanced non-small cell lung cancer. Methods RCTs of Fuzheng Kang＇ ai formula combined with chemotherapy in treating patients with advanced non-small cell lung cancer were relieved from CMBdisc, PubMed database etc. RevMan 5.2 was adopted to carry out Meta analysis. Results A total of 6 RCTs with B-class and 467 NSCLC patients were enrolled. Meta analysis results showed the effective rate of Fuzheng Kang＇ ai formula combined with chemotherapy was superior to that of simple chemotherapy, with statistically significant difference [ RR = 1.87,95 % CI （ 1.28 - 2.72 ） ]. And incidence rate of ADR of Fuzheng Kang＇ ai formula combined with chemotherapy was lower than that of simple chemotherapy, with difference being statistically significant [ RR = 0. 29,95% CI （0. 16 - 0.54 ） ]. The obvious publishing bias was not found. Conclusion Existing evidence showed that the effective rate of Fuzheng Kang＇ ai formula combined with chemotherapy is superior to simple chemotherapy, and the former has better safety.

关 键 词：扶正抗癌方 晚期非小细胞肺癌 疗效 META分析 

分 类 号：R734.2[医药卫生—肿瘤]